Morgan Stanley
IKT icon

Morgan Stanley’s Inhibikase Therapeutics IKT Stock Holding History

Morgan Stanley’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Sell
114,006
-50,253
-31% -$89.9K ﹤0.01% 5893
2026
Q1 		$276K Buy
164,259
+84,577
+106% +$150K ﹤0.01% 5732
2025
Q4 		$163K Buy
79,682
+23,663
+42% +$37.7K ﹤0.01% 6007
2025
Q3 		$90.8K Sell
56,019
-43,659
-44% -$75.6K ﹤0.01% 6193
2025
Q2 		$194K Buy
99,678
+78,032
+360% +$153K ﹤0.01% 5862
2025
Q1 		$47.4K Buy
21,646
+14,350
+197% +$36K ﹤0.01% 6286
2024
Q4 		$23.7K Buy
7,296
+5,629
+338% +$14K ﹤0.01% 6516
2024
Q3 		$2.17K Hold
1,667
– – ﹤0.01% 7117
2024
Q2 		$2.02K Hold
1,667
– – ﹤0.01% 7066
2024
Q1 		$3.6K Hold
1,667
– – ﹤0.01% 6962
2023
Q4 		$2.12K Hold
1,667
– – ﹤0.01% 7031
2023
Q3 		$2.32K Hold
1,667
– – ﹤0.01% 7100
2023
Q2 		$6.02K Hold
1,667
– – ﹤0.01% 6942
2023
Q1 		$6.58K Hold
1,667
– – ﹤0.01% 6997
2022
Q4 		$5K Hold
1,667
– – ﹤0.01% 7145
2022
Q3 		$9K Hold
1,667
– – ﹤0.01% 7107
2022
Q2 		$7K Buy
+1,667
New +$9.83K ﹤0.01% 7320
2022
Q1 		– Hold
0
– – – 8031
2021
Q4 		– Hold
0
– – – 8028

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley's IKT Position: Q2 2026 in Review

Morgan Stanley reduced its Inhibikase Therapeutics (IKT) stake by 31% in Q2 2026, selling an estimated $89.9K and leaving 114,006 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #5893.

Morgan Stanley first reported a position in IKT in Q2 2022 and has held it in 17 quarters since. The position peaked at $276K in Q1 2026. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Morgan Stanley held 114,006 shares of Inhibikase Therapeutics worth $231K as of Q2 2026.
  • Morgan Stanley sold 50,253 Inhibikase Therapeutics shares in Q2 2026, an estimated $89.9K.
  • Inhibikase Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5893 holding.
  • Morgan Stanley first reported a position in Inhibikase Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Morgan Stanley's Inhibikase Therapeutics position peaked at $276K in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.